IDEAYA Biosciences (IDYA) 10-Q 10 Aug 23 2023 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2023	Aug. 04, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Trading Symbol	IDYA
Entity Registrant Name	IDEAYA Biosciences, Inc.
Entity Central Index Key	0001676725
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		57,559,234
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Security Exchange Name	NASDAQ
Entity File Number	001-38915
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-4268251
Entity Address, Address Line One	7000 Shoreline Court
Entity Address, Address Line Two	Suite 350
Entity Address, City or Town	South San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94080
City Area Code	650
Local Phone Number	443-6209
Document Quarterly Report	true
Document Transition Report	false

Condensed Balance Sheets

Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 102,843	$ 68,632
Short-term marketable securities	390,873	296,197
Accounts receivable	160	211
Prepaid expenses and other current assets	7,912	5,414
Total current assets	501,788	370,454
Restricted cash	722	106
Long-term marketable securities	16,377	8,317
Property and equipment, net	6,829	6,509
Right-of-use assets	1,733	2,484
Other non-current assets	108	99
Total assets	527,557	387,969
Current liabilities
Accounts payable	5,868	4,280
Accrued liabilities	14,690	16,999
Contract liability	2,818	8,568
Operating lease liabilities - current	1,961	1,871
Total current liabilities	25,337	31,718
Long-term contract liability		5,185
Long-term operating lease liabilities	611	1,611
Total liabilities	25,948	38,514
Commitments and contingencies (Note 5)
Stockholders’ equity
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of June 30, 2023 and December 31, 2022; no shares issued and outstanding as of June 30, 2023 and December 31, 2021
Common stock, $0.0001 par value, 300,000,000 shares authorized as of June 30, 2023 and December 31, 2022; 57,440,328 and 48,193,179 shares issued and outstanding as of June 30, 2023 and December 31, 2022	6	5
Additional paid-in capital	789,751	587,724
Accumulated other comprehensive loss	(1,179)	(2,871)
Accumulated deficit	(286,969)	(235,403)
Total stockholders’ equity	501,609	349,455
Total liabilities and stockholders’ equity	$ 527,557	$ 387,969

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	57,440,328	48,193,179
Common stock, shares outstanding	57,440,328	48,193,179

Condensed Statements of Operati

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Collaboration revenue	$ 3,544	$ 5,851	$ 11,424	$ 17,210
Operating expenses
Research and development	29,178	22,796	57,037	42,451
General and administrative	7,075	5,554	13,375	11,478
Total operating expenses	36,253	28,350	70,412	53,929
Loss from operations	(32,709)	(22,499)	(58,988)	(36,719)
Interest income and other income, net	4,783	443	7,422	650
Net loss	(27,926)	(22,056)	(51,566)	(36,069)
Unrealized gains (losses) on marketable securities	226	(825)	1,692	(2,917)
Comprehensive loss	$ (27,700)	$ (22,881)	$ (49,874)	$ (38,986)
Net loss per common share, basic	$ (0.50)	$ (0.57)	$ (0.99)	$ (0.93)
Net loss per common share, diluted	$ (0.50)	$ (0.57)	$ (0.99)	$ (0.93)
Weighted average number of common shares outstanding used in computing net loss per share, basic	56,251,130	38,660,971	52,332,373	38,626,659
Weighted average number of common shares outstanding used in computing net loss per share, diluted	56,251,130	38,660,971	52,332,373	38,626,659

Condensed Statements of Stockho

Condensed Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Follow On Public Offering	At The Market Offering	Common Stock	Common Stock Follow On Public Offering	Common Stock At The Market Offering	Additional Paid-In Capital	Additional Paid-In Capital Follow On Public Offering	Additional Paid-In Capital At The Market Offering	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance at Dec. 31, 2021	$ 301,514			$ 4			$ 478,970			$ (712)	$ (176,748)
Beginning balance, shares at Dec. 31, 2021				38,533,045
Issuance of common stock, net of issuance cost			$ (75)						$ (75)
Issuance of common stock, net of issuance costs, shares						2,173
Issuance of common stock upon exercise of stock options	784						784
Issuance of common stock upon exercise of stock options, shares				122,913
Employee stock purchase plan (ESPP) purchase	435						435
Employee stock purchase plan (ESPP) purchase, shares				45,879
Stock-based compensation	5,649						5,649
Other comprehensive income (loss)	(2,917)									(2,917)
Net loss	(36,069)										(36,069)
Ending balance at Jun. 30, 2022	269,321			$ 4			485,763			(3,629)	(212,817)
Ending balance, shares at Jun. 30, 2022				38,704,010
Beginning balance at Mar. 31, 2022	288,667			$ 4			482,228			(2,804)	(190,761)
Beginning balance, shares at Mar. 31, 2022				38,639,922
Issuance of common stock, net of issuance cost			(66)						(66)
Issuance of common stock upon exercise of stock options	122						122
Issuance of common stock upon exercise of stock options, shares				18,209
Employee stock purchase plan (ESPP) purchase	435						435
Employee stock purchase plan (ESPP) purchase, shares				45,879
Stock-based compensation	3,044						3,044
Other comprehensive income (loss)	(825)									(825)
Net loss	(22,056)										(22,056)
Ending balance at Jun. 30, 2022	269,321			$ 4			485,763			(3,629)	(212,817)
Ending balance, shares at Jun. 30, 2022				38,704,010
Beginning balance at Dec. 31, 2022	349,455			$ 5			587,724			(2,871)	(235,403)
Beginning balance, shares at Dec. 31, 2022				48,193,179
Issuance of common stock, net of issuance cost		$ 153,590	2,425		$ 1			$ 153,589	2,425
Issuance of common stock, net of issuance costs, shares					8,858,121	152,284
Issuance of pre-funded warrants to purchase common stock	35,132						35,132
Issuance of common stock upon exercise of stock options	1,854						1,854
Issuance of common stock upon exercise of stock options, shares				194,590
Employee stock purchase plan (ESPP) purchase	637						637
Employee stock purchase plan (ESPP) purchase, shares				42,154
Stock-based compensation	8,390						8,390
Other comprehensive income (loss)	1,692									1,692
Net loss	(51,566)										(51,566)
Ending balance at Jun. 30, 2023	501,609			$ 6			789,751			(1,179)	(286,969)
Ending balance, shares at Jun. 30, 2023				57,440,328
Beginning balance at Mar. 31, 2023	333,810			$ 5			594,253			(1,405)	(259,043)
Beginning balance, shares at Mar. 31, 2023				48,390,394
Issuance of common stock, net of issuance cost		$ 153,590	$ (78)		$ 1			$ 153,589	$ (78)
Issuance of common stock, net of issuance costs, shares					8,858,121	10,124
Issuance of pre-funded warrants to purchase common stock	35,132						35,132
Issuance of common stock upon exercise of stock options	1,487						1,487
Issuance of common stock upon exercise of stock options, shares				139,535
Employee stock purchase plan (ESPP) purchase	637						637
Employee stock purchase plan (ESPP) purchase, shares				42,154
Stock-based compensation	4,731						4,731
Other comprehensive income (loss)	226									226
Net loss	(27,926)										(27,926)
Ending balance at Jun. 30, 2023	$ 501,609			$ 6			$ 789,751			$ (1,179)	$ (286,969)
Ending balance, shares at Jun. 30, 2023				57,440,328

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities
Net loss	$ (51,566)	$ (36,069)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	1,207	974
Net amortization (accretion) of premiums (discounts) on marketable securities	(4,111)	518
Stock-based compensation	8,390	5,649
Amortization of right-of-use assets	751	694
Changes in assets and liabilities
Accounts receivable	51	815
Prepaid expenses and other assets	(2,508)	(51)
Accounts payable	1,589	1,916
Accrued and other liabilities	(3,260)	3,099
Contract liabilities	(10,935)	(16,358)
Lease liabilities	(910)	(826)
Net cash used in operating activities	(61,302)	(39,639)
Cash flows from investing activities
Purchases of property and equipment, net	(927)	(2,342)
Purchases of marketable securities	(292,543)	(102,222)
Maturities of marketable securities	195,610	100,119
Net cash used in investing activities	(97,860)	(4,445)
Cash flows from financing activities
Proceeds from issuance of common stock upon public offering, net of issuance costs	153,840	0
Proceeds from issuance of common stock related to at-the-market offering program, net of issuance costs	2,526	(75)
Proceeds from issuance of pre-funded warrants to purchase common stock, net of issuance costs	35,132	0
Proceeds from ESPP purchase	637	784
Proceeds from exercise of common stock options	1,854	435
Net cash provided by financing activities	193,989	1,144
Net increase (decrease) in cash, cash equivalents and restricted cash	34,827	(42,940)
Cash, cash equivalents and restricted cash, at beginning of period	68,738	92,152
Cash, cash equivalents and restricted cash, at end of period	103,565	49,212
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents	102,843	49,106
Restricted cash	722	106
Cash, cash equivalents and restricted cash	103,565	49,212
Supplemental disclosure of cash flow information:
Cash paid for interest	26	32
Supplemental non-cash investing and financing activities:
Purchases of property and equipment in accounts payable and accrued liabilities	600	1,021
Unpaid offering costs	$ 351	$ 0

Organization

Organization	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	1. Organization Description of the Business IDEAYA Biosciences, Inc. (the “Company”) is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The Company is headquartered in South San Francisco, California and was incorporated in the State of Delaware in June 2015. To date, the Company has been primarily engaged in business planning, research, development, recruiting and raising capital. 2023 Public Offering and Sale of IDEAYA Common Stock and Pre-Funded Warrants On April 27, 2023, the Company completed an underwritten public follow-on offering. The offering consisted of 8,858,121 shares of our common stock at an offering price to the public of $ 18.50 per share, including 1,418,920 shares of common stock upon the exercise in full of the overallotment option by the underwriters, as well as pre-funded warrants to purchase 2,020,270 shares of common stock at a public offering price of $ 18.4999 per underlying share, in each case before underwriting discounts and commissions. Pursuant to the offering, we received aggregate gross proceeds of approximately $ 201.3 million, before deducting underwriting discounts and commissions and other offering expenses, resulting in net proceeds of approximately $ 188.7 million, after deducting underwriting discounts and commissions and other offering expenses. Prospectus Supplement - At-the-Market Facility Our Registration Statement on Form S-3, which was filed under the Securities Act of 1933, as amended (the “Securities Act”), and became effective as of June 10, 2020, lapsed in June 2023. The January 2021 Sales Agreement was automatically terminated concurrently therewith. As of the termination date of the January 2021 Sales Agreement, approximately $ 61.8 million of common stock remained available to be sold under the at-the-market facility associated therewith. On June 26, 2023, we filed a new Registration Statement on Form S-3 (File No. 333- 272936) under the Securities Act as an automatic shelf registration statement as a “well-known seasoned issuer”, as defined in Rule 405 under the Securities Act. On June 26, 2023, we also entered into a new Open Market Sales Agreement, or June 2023 Sales Agreement, with Jefferies LLC (“Jefferies”) relating to an at-the-market offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, par value $ 0.0001 per share, having aggregate gross proceeds of up to $ 250.0 million through Jefferies as sales agent. For the three months ended June 30, 2023, we incurred $ 0.3 million of other offering expenses which was recorded to Additional Paid-in Capital. During the reporting period for the quarter ended June 30, 2023, we sold an aggregate of 10,124 share of our common stock for aggregate net proceeds of $ 0.2 million at a weighted average sales price of approximately $ 23.52 per share under the at-the-market offering pursuant to the June 2023 Sales Agreement. As of June 30, 2023, $ 249.8 million of common stock remained available to be sold under the at-the-market facility associated with the June 2023 Sales Agreement. We may cancel our at-the-market program at any time upon written notice, pursuant to its terms. Liquidity The Company has incurred significant losses and negative cash flows from operations and had an accumulated deficit of $ 287.0 million as of June 30, 2023. The Company has historically financed its operations primarily through the sale of convertible notes, redeemable convertible preferred stock and common stock, and payments received from its collaboration arrangement. To date, none of the Company’s product candidates have been approved for sale, and the Company has not generated any revenue from commercial products since inception. Management expects operating losses to continue and increase for the foreseeable future, as the Company progresses into clinical development activities for its lead product candidates. The Company’s prospects are subject to risks, expenses and uncertainties frequently encountered by companies in the biotechnology industry as discussed under Risks and Uncertainties in Note 2. While the Company has been able to raise multiple rounds of financing, there can be no assurance that in the event the Company requires additional financing, such financing will be available on terms which are favorable or at all. Failure to generate sufficient cash flows from operations, raise additional capital or reduce certain discretionary spending would have a material adverse effect on the Company’s ability to achieve its intended business objectives. As of June 30, 2023, the Company had cash, cash equivalents and marketable securities of $ 510.1 million. Management believes that the Company’s current cash, cash equivalents and marketable securities will be sufficient to fund its planned operations for at least 12 months from the date of the issuance of these financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim reporting. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, the unaudited condensed financial statements should be read in conjunction with the audited financial statements and the related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC. Unaudited Condensed Financial Statements The accompanying financial information for the three and six months ended June 30, 2023 and June 30, 2022 are unaudited. The unaudited condensed financial statements have been prepared on the same basis as the annual audited financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position as of June 30, 2023 and its results of operations for the three and six months ended June 30, 2023 and June 30, 2022 and cash flows for the six months ended June 30, 2023 and June 30, 2022 . The results for interim periods are not necessarily indicative of the results expected for the full fiscal year or any other periods. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include useful lives of property and equipment, determination of the discount rate for operating leases, accruals for research and development activities, revenue recognition, stock-based compensation, and income taxes. On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates. Risks and Uncertainties The Company operates in a dynamic and highly competitive industry and is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, contract manufacturers, contract research organizations and collaboration partners, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies and clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. The Company believes that changes in any of the following areas could have a material adverse effect on the Company’s future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials and collaboration activities; regulatory approval and market acceptance of the Company’s products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company’s ability to attract and retain employees necessary to support its growth. Products developed by the Company require approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained or maintained, that the products will receive the necessary approvals, or that any approved products will be commercially viable. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval, it could have a materially adverse impact on the Company. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties. Beginning in late 2019, the outbreak of a novel strain of virus named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), or coronavirus, which causes coronavirus disease 2019, or COVID-19, has evolved into a global pandemic. The extent of the impact of the coronavirus outbreak on the Company’s business will depend on certain developments, including the duration and spread of the outbreak and the extent and severity of the impact on the Company’s clinical trial activities, research activities and suppliers, all of which are uncertain and cannot be predicted. At this point, the extent to which the coronavirus outbreak may materially impact the Company’s financial condition, liquidity or results of operations is uncertain. The Company has expended and will continue to expend substantial funds to complete the research, development and clinical testing of product candidates. The Company also will be required to expend additional funds to establish commercial-scale manufacturing arrangements and to provide for the marketing and distribution of products that receive regulatory approval. The Company may require additional funds to commercialize its products. The Company is unable to entirely fund these efforts with its current financial resources. If adequate funds are unavailable on a timely basis from operations or additional sources of financing, the Company may have to delay, reduce the scope of or eliminate one or more of its research or development programs which would materially and adversely affect its business, financial condition and operations. Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. Substantially all the Company’s cash is held by two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company’s investment policy addresses credit ratings, diversification, and maturity dates. The Company invests its cash equivalents and marketable securities in money market funds, U.S. government securities, commercial paper, and corporate bonds. The Company limits its credit risk associated with cash equivalents and marketable securities by placing them with banks and institutions it believes are creditworthy and in highly rated investments and, by policy, limits the amount of credit exposure with any one commercial issuer. The Company has not experienced any credit losses on its deposits of cash, cash equivalents or marketable securities. Accounts receivable represents amounts due from GSK. The Company monitors economic conditions to identify facts or circumstances that may indicate that any of its accounts receivable are at risk of collection. Summary of Significant Accounting Policies There have been no material changes in the accounting policies from those disclosed in the financial statements and the related notes included in the Company's Annual Report on Form 10-K, filed with the SEC on March 7, 2023. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) under its accounting standard codifications (“ASC”) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below. New Accounting Pronouncements Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes will result in earlier recognition of credit losses. For public business entities, this ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The FASB subsequently issued supplemental guidance to ASC 326 within ASU 2019-05, Financial Instruments—Credit Losses (Topic 326): Targeted Transition Relief , ASU 2019-10, Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) and ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments—Credit Losses . ASU 2019-05 provides an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. ASU 2019-10 extended the effectiveness of Topic 326 for smaller reporting companies until fiscal years beginning after December 15, 2022. ASU 2019-10 requires entities to make a one-time determination of whether an entity is eligible to be a smaller reporting company as of November 15, 2019 for the purpose of determining the effective date of ASU 2016-13. The Company determined that it was eligible to be a smaller reporting company as of November 15, 2019. The Company adopted this ASU on January 1, 2023 , and evaluated the impact of the adoption of the ASU. It did no t result in a material impact on the Company's financial statements and related disclosures.

Fair Value Measurement and Mark

Fair Value Measurement and Marketable Securities	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurement and Marketable Securities	3. Fair Value Measurement and Marketable Securities The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: Level 1—Observable inputs, such as quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3—Unobservable inputs which reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model . In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. As of June 30, 2023, financial assets measured and recognized at fair value are as follows (in thousands): June 30, 2023 Amortized Gross Gross Estimated Assets U.S. government securities Level 2 $ 300,981 $ 17 $ ( 944 ) $ 300,054 Corporate bonds Level 2 42,167 — ( 214 ) 41,953 Commercial paper (1) Level 2 135,497 — ( 38 ) 135,459 Marketable securities 478,645 17 ( 1,196 ) 477,466 Money market funds (2) Level 1 32,160 — — 32,160 Total fair value of assets $ 510,805 $ 17 $ ( 1,196 ) $ 509,626 (1) $ 70.2 million was included in cash and cash equivalents on the balance sheet due to securities with purchase dates within 90 days of maturity dates (2) Included in cash and cash equivalents on the condensed balance sheets. As of December 31, 2022, financial assets measured and recognized at fair value are as follows (in thousands): December 31, 2022 Amortized Gross Gross Estimated Assets U.S. government securities Level 2 $ 146,030 $ — $ ( 2,291 ) $ 143,739 Corporate bonds Level 2 86,546 — ( 580 ) 85,966 Commercial paper (1) Level 2 78,797 — — 78,797 Marketable securities 311,373 — ( 2,871 ) 308,502 Money market funds (2) Level 1 64,153 — — 64,153 Total fair value of assets $ 375,526 $ — $ ( 2,871 ) $ 372,655 (1) $ 4.0 million was included in cash and cash equivalents on the balance sheet due to securities with purchase dates within 90 days of maturity dates (2) Included in cash and cash equivalents on the condensed balance sheets. The Company considers available evidence in evaluating potential other-than-temporary impairments of its marketable securities, including the duration and extent to which fair value is less than cost, and the Company’s ability and intent to hold the investment. As of June 30, 2023 and December 31, 2022, the Company held certain securities in an unrealized loss position. These unrealized losses were considered to be temporary as the Company expects to recover the entire amortized cost basis on the securities in unrealized loss positions based on the creditworthiness of the underlying issuer, and the Company neither intends to sell these securities nor considers it more likely than not that the Company would be required to sell any such security before its anticipated recovery. As a result, the Company did not consider any of these investments to be other-than-temporarily impaired at June 30, 2023 and December 31, 2022. As of June 30, 2023 and December 31, 2022 , all marketable securities had a remaining maturity of less than two years . There were no financial liabilities measured and recognized at fair value as of June 30, 2023 and December 31, 2022 .

Balance Sheet Components

Balance Sheet Components	6 Months Ended
	Jun. 30, 2023
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Components	4. Balance Sheet Components Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): Useful Life June 30, December 31, (In Years) 2023 2022 Laboratory equipment 5 $ 10,859 $ 9,743 Computer equipment 3 261 261 Software 3 231 231 Leasehold improvements Shorter of useful life or lease term 3,321 3,321 Furniture and fixtures 5 506 506 Total property and equipment 15,178 14,062 Less: Accumulated depreciation and amortization ( 8,349 ) ( 7,553 ) Property and equipment, net $ 6,829 $ 6,509 Depreciation and amortization expense was $ 0.6 million and $ 0.5 million for the three months ended June 30, 2023 and June 30, 2022, respectively, and $ 1.2 million and $ 1.0 million for the six months ended June 30, 2023 and June 30, 2022, respectively. Accrued Liabilities Accrued liabilities consisted of the following (in thousands): June 30, December 31, 2023 2022 Accrued research and development expenses $ 8,481 $ 11,146 Accrued salaries and benefits 4,500 5,248 Legal and professional fees 764 513 Other 945 92 Accrued liabilities $ 14,690 $ 16,999

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	5. Commitments and Contingencies Contingencies From time to time, the Company may be involved in litigation related to claims that arise in the ordinary course of its business activities. The Company accrues for these matters when it is probable that future expenditures will be made and these expenditures can be reasonably estimated. As of June 30, 2023, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s financial position, results of operations or cash flows. Indemnification The Company enters into standard indemnification arrangements in the ordinary course of business with vendors, clinical trial sites and other parties. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company has not recorded a liability related to such indemnification agreements as of June 30, 2023 .

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	6. Income Taxes For the three and six months ended June 30, 2023 and June 30, 2022 , the Company did no t record a federal or state income tax provision due to its recurring net losses. In addition, the Company has taken a full valuation allowance against its net deferred tax assets as the Company believes it is not more likely than not that the benefit will be realized. Under the Tax Cuts and Jobs Act, for tax years beginning after December 31, 2021, taxpayers are required to capitalize certain research and experimental expenditures and amortize them over five or fifteen years pursuant to the Internal Revenue Code Section 174. Previously, such costs may be deducted in the period they are incurred. As of June 30, 2023 , the Company has performed a high-level assessment of the potential tax impact related to this change in tax law and does not expect to have any material tax impact for the year ending December 31, 2023.

Common Stock

Common Stock	6 Months Ended
	Jun. 30, 2023
Stockholders' Equity Note [Abstract]
Common Stock	7. Common Stock As of June 30, 2023 and December 31, 2022 , the Company’s certificate of incorporation authorized the Company to issue 300,000,000 shares of common stock at a par value of $ 0.0001 per share. Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Company’s board of directors. As of June 30, 2023 and December 31, 2022 , no dividends have been declared to date. On April 27, 2023, the Company completed an underwritten public follow-on offering. The offering consisted of 8,858,121 shares of our common stock at an offering price to the public of $ 18.50 per share, including 1,418,920 shares of common stock upon the exercise in full of the overallotment option by the underwriters, as well as pre-funded warrants (the “Warrants”) to purchase 2,020,270 shares of common stock at a public offering price of $ 18.4999 per underlying share, in each case before underwriting discounts and commissions. Pursuant to the offering, we received aggregate gross proceeds of approximately $ 201.3 million, before deducting underwriting discounts and commissions and other offering expenses, resulting in net proceeds of approximately $ 188.7 million, after deducting underwriting discounts and commissions and other offering expenses. As of June 30, 2023, the following aggregate warrants to purchase shares of the Company’s common stock were issued and outstanding: Issue Date Expiration Date Exercise Price per Share Number of Shares subject to Outstanding Warrants April 27, 2023 None $ 0.0001 2,020,270 The Warrants are classified as a component of Stockholders’ Equity within Additional Paid-in-Capital. The Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, are indexed to the Company’s common stock and meet the equity classification criteria. The Warrants will not expire until they are fully exercised. As of June 30, 2023, no shares underlying the Warrants had been exercised. The Company had reserved common stock for future issuance as follows: June 30, December 31, 2023 2022 Outstanding options under the 2015 and 2019 Plans 7,138,527 5,097,263 Shares available for grant under the 2019 Plan 656,992 664,919 Shares available for grant under the 2023 Inducement Plan 699,800 — Shares available under the Employee Stock Purchase Plan 1,346,300 906,523 Pre-funded warrants issued and outstanding 2,020,270 — Total 11,861,889 6,668,705

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	8. Stock-Based Compensation 2023 Inducement Plan On February 24, 2023, the Company adopted the IDEAYA Biosciences, Inc. 2023 Employment Inducement Award Plan (the “2023 Inducement Plan”), pursuant to which the Company reserved 1,000,000 shares of its common stock to be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company as an inducement material to the individual’s entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The 2023 Inducement Plan was approved by the Company’s board of directors without stockholder approval in accordance with such rule. Options granted under the 2023 Inducement Plan have a term of 10 years and generally vest over a 4-year period with 1-year cliff vesting. As of June 30, 2023 , the number of shares available for issuance under the 2023 Inducement Plan was 699,800 . 2019 Incentive Award Plan In May 2019, the Company’s board of directors adopted and the Company’s stockholders approved the 2019 Incentive Award Plan (the “2019 Plan”), under which the Company may grant cash and equity-based incentive awards to the Company’s employees, consultants and directors. Following the effectiveness of the 2019 Plan, the Company will not make any further grants under the 2015 Equity Incentive Plan (the “2015 Plan”). However, the 2015 Plan continues to govern the terms and conditions of the outstanding awards granted under it. Shares of common stock subject to awards granted under the 2015 Plan that are forfeited or lapse unexercised and which following the effective date of the 2019 Plan are not issued under the 2015 Plan will be available for issuance under the 2019 Plan. Options granted under the 2019 Plan may be either incentive stock options (“ISOs”) or nonqualified stock options (“NSOs”). ISOs may be granted only to Company employees (including officers and directors who are also employees). NSOs may be granted to Company employees and consultants. The 2019 Plan is subject to an annual increase on the first day of each year beginning in 2020 and ending in 2029, equal to the lesser of 4 % of the shares outstanding on the last day of the immediately preceding fiscal year, and such small number of shares as determined by the Company's board of directors. Options granted under the 2019 Plan have a term of 10 years (or five years if granted to a 10% stockholder) and generally vest over a 4 -year period with 1 -year cliff vesting. As of June 30, 2023 , the number of shares available for issuance under the 2019 Plan was 656,992 . 2015 Equity Incentive Plan In 2015, the Company established its 2015 Plan which provides for the granting of stock options to employees and consultants of the Company. Options granted under the 2015 Plan may be either ISOs or NSOs. 2019 Employee Stock Purchase Plan In May 2019, the Company’s board of directors adopted and the Company’s stockholders approved the 2019 Employee Stock Purchase Plan (the “ESPP”). The ESPP provides eligible employees with the opportunity to acquire an ownership interest in the Company through periodic payroll deductions up to 15 % of eligible compensation. The offering period is determined by the Company in its discretion but may not exceed 27 months. The per-share purchase price on the applicable exercise date for an offering period is equal to the lesser of 85 % of the fair market value of the common stock at either the first business day or last business day of the offering period, provided that no more than 4,000 shares of common stock may be purchased by any one employee during each offering period. The ESPP is intended to constitute an “employee stock purchase plan” under Section 423(b) of the Internal Revenue Code of 1986, as amended. A total of 195,000 shares of common stock were initially reserved for issuance under the ESPP, subject to an annual increase on January 1 of each year, beginning on January 1, 2020, equal to the lesser of 1 % of the shares outstanding on the last day of the immediately preceding fiscal year and such number of shares as may be determined by the Company's board of directors, provided, however, that no more than 2,500,000 shares may be issued under the ESPP. As of June 30, 2023, a total of 1,346,300 shares of common stock were reserved for issuance under the ESPP, subject to an annual increase on January 1 of each year. For the six months ended June 30, 2023 and June 30, 2022, the Company recorded $ 0.3 million and $ 0.2 million, respectively, of compensation expense related to participation in the ESPP. Stock-Based Compensation Expense Total stock-based compensation expense recorded related to awards granted to employees and non-employees was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Research and development $ 2,705 $ 1,603 $ 4,792 $ 2,901 General and administrative 2,026 1,441 3,598 2,748 Total stock-based compensation expense $ 4,731 $ 3,044 $ 8,390 $ 5,649 Stock Options Activity under the Company’s 2015 and 2019 Plans and 2023 Inducement Plan is set forth below: Outstanding Options Shares Weighted- Weighted- Aggregate Intrinsic Value (Millions) Balance, January 1, 2023 5,097,263 $ 12.93 7.84 $ 29.58 Options granted 2,433,571 $ 18.06 Options exercised ( 194,590 ) $ 9.52 Options canceled ( 197,717 ) $ 17.80 Balance, June 30, 2023 7,138,527 $ 14.64 8.15 $ 63.08 Exercisable as of June 30, 2023 2,849,704 $ 11.32 6.64 $ 34.54 Vested and expected to vest as of 7,138,527 $ 14.64 8.15 $ 63.08 The weighted-average grant-date fair value of options granted during the six months ended June 30, 2023 and June 30, 2022 was $ 13.34 and $ 9.43 per share, respectively. The aggregate intrinsic value of options exercised for the six months ended June 30, 2023 and June 30, 2022 was $ 1.9 million and $ 1.0 million, respectively. Intrinsic values are calculated as the difference between the exercise price of the underlying options and the fair value of the common stock on the date of exercise. As of June 30, 2023 and December 31, 2022, total unrecognized stock-based compensation expense for stock options was $ 50.5 million and $ 28.0 million, respectively, which is expected to be recognized over a weighted-average period of 2.88 years and 2.65 years, respectively. Black-Scholes Assumptions The fair values of options were calculated using the assumptions set forth below: Three Months Ended June 30, Six months Ended June 30, 2023 2022 2023 2022 Expected term 6.1 years 6.1 years 6.1 years 6.1 years Expected volatility 85.2 % - 86.4 % 87.5 % - 87.8 % 85.2 % - 86.9 % 87.5 % - 89.9 % Risk-free interest rate 3.6 % - 4.1 % 2.7 % - 3.0 % 3.6 % - 4.1 % 1.6 % - 3.0 % Dividend yield 0 % 0 % 0 % 0 % Expected term . The expected term represents the weighted-average period the stock options are expected to remain outstanding and is based on the options’ vesting terms, contractual terms and industry peers, as the Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. Expected Volatility . The expected volatility is based on the Company's historical stock price volatility. The historical stock price volatility is calculated based on a period of time commensurate with the expected term assumption for each grant. Risk-Free Interest Rate . The risk-free rate assumption is based on U.S. Treasury instruments whose term was consistent with the expected term of the Company’s stock options. Expected Dividend Rate . The Company has not paid and does not anticipate paying any dividends in the near future. Accordingly, the Company has estimated the dividend yield to be zero . The Company accounts for forfeitures as they occur. Fair Value of Common Stock The fair value of the Company’s common stock is determined based on its closing market price on the date of grant.

Significant Agreements

Significant Agreements	6 Months Ended
	Jun. 30, 2023
Significant Agreements [Abstract]
Significant Agreements	9. Significant Agreements GSK Collaboration, Option and License Agreement In June 2020, the Company entered into a Collaboration, Option and License Agreement (the “GSK Collaboration Agreement”), with an affiliate of GSK plc, GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4), Limited (“GSK”), pursuant to which the Company and GSK have entered into a collaboration for its synthetic lethality programs targeting methionine adenosyltransferase 2a, or MAT2A, DNA Polymerase Theta, or Pol Theta or POLQ, and Werner Helicase, or WRN. On July 27, 2020 (the “Effective Date”), the Company and GSK received Hart-Scott-Rodino Antitrust Improvements Act clearance, or HSR Clearance, and the GSK Collaboration Agreement became effective. Pursuant to the GSK Collaboration Agreement, GSK paid the Company $ 100.0 million on July 31, 2020. As of June 30, 2023, GSK has made aggregate payments to the Company in the amount of $ 3.0 million for the achievement of certain development and regulatory milestones with respect to a POLQ product. MAT2A Program Under the MAT2A program, the Company led research and development through early clinical development stage, and GSK had an exclusive option to obtain an exclusive license to continue development of and commercialize MAT2A products arising out of the MAT2A program, or the Option. The Company delivered an Option data package to GSK resulting from its conduct of a dose escalation portion of a MAT2A Phase 1 monotherapy clinical trial pursuant to the GSK Collaboration Agreement, following which the Option was exercisable within a specified time period. In August 2022, the Company received notice from GSK waiving its rights to exercise its Option to obtain an exclusive license to further develop and commercialize IDE397, as well as other IDEAYA compounds, if any, directly targeting MAT2A pursuant to the GSK Collaboration Agreement. As such, the Company retains and fully owns all right, title and interest in and to IDE397 and the MAT2A program, including all worldwide commercial rights thereto. The Company will be responsible for the costs of further research and clinical development activities that the Company conducts for the MAT2A program. The Option was deemed a material right under the GSK Collaboration Agreement. See Note 10, Revenue Recognition, for more information. GSK had a right to initiate, or to request that the Company initiate, a Phase 1 combination clinical trial for a MAT2A product and GSK’s Type I PRMT inhibitor (GSK3368715) product, or the MAT2A Combination Trial, prior to GSK’s waiver of its rights to exercise its Option. GSK would have been solely responsible for costs of the conduct of the MAT2A Combination Trial, except for supply of the MAT2A product therefor, which would be provided by the Company at its own cost. On January 31, 2022, GSK notified the Company of its decision to not proceed with the MAT2A Combination Trial under the GSK Collaboration Agreement. Pol Theta Program Pursuant to the GSK Collaboration Agreement, GSK holds a global, exclusive license to develop and commercialize POLQ products arising out of the POLQ program. GSK and the Company will collaborate on ongoing preclinical research for the POLQ program, and GSK will lead clinical development for the POLQ program. GSK will be responsible for all research and development costs for the POLQ program, including those incurred by the Company. The Company will be eligible to receive future development and regulatory milestones of up to $ 485.0 million, with respect to each POLQ product, including as applicable, for multiple POLQ products that target certain alternative protein domains or are based on alternative modalities. Additionally, the Company is eligible to receive up to $ 475.0 million of commercial milestones with respect to each POLQ product. The Company is also entitled to receive tiered royalties on global net sales of POLQ products by GSK, its affiliates and their sublicensees ranging from high single digit to sub-teen double digit percentages, subject to certain customary reductions. In June 2022, the Company announced the nomination of a Pol Theta Helicase inhibitor development candidate (“DC”) and in August 2022, announced the achievement of an initial preclinical development milestone in connection with ongoing IND-enabling studies to support evaluation of Pol Theta Helicase Inhibitor DC, triggering a $ 3.0 million milestone payment, which the Company received in October 2022. The Company has the potential to receive up to an additional $ 7.0 million for advancing the Pol Theta Helicase Inhibitor DC through IND effectiveness. WRN Program Pursuant to the GSK Collaboration Agreement, GSK holds a global, exclusive license to develop and commercialize WRN products arising out of the WRN program. The Company and GSK will collaborate on ongoing preclinical research for the WRN program, and GSK will lead clinical development for the WRN program, with IDEAYA responsible for 20 % and GSK responsible for 80 % of such global research and development costs. The cost-sharing percentages will be adjusted based on the actual ratio of U.S. to global profits for WRN products, as measured three and six years after global commercial launch thereof. The Company will be eligible to receive future development milestones of up to $ 485.0 million, with respect to each WRN product, including as applicable, for multiple WRN products that are based on alternative modalities. Additionally, the Company will be eligible to receive up to $ 475.0 million of commercial milestones with respect to each WRN product. The Company will be entitled to receive 50 % of U.S. net profits and tiered royalties on global non-U.S. net sales of WRN products by GSK, its affiliates and their sublicensees ranging from high single digit to sub-teen double digit percentages, subject to certain customary reductions. The Company will have a right to opt-out of the 50 % U.S. net profit share and corresponding research and development cost share for the WRN program, and would be eligible to receive tiered royalties on U.S. net sales of WRN products by GSK, its affiliates and their sublicensees at the same royalty rates as for global non-U.S. net sales thereafter, with economic adjustments based on the stage of the WRN program at the time of opt-out. General Under the terms of the GSK Collaboration Agreement, subject to certain exceptions, the Company and GSK will not, directly or through third parties, develop or commercialize other products whose primary and intended mechanism of action is the modulation of WRN, POLQ, or MAT2A prior to the GSK MAT2A Option Waiver for an agreed upon period of time. Such restriction has ceased to apply with respect to MAT2A following GSK waiver of its right to exercise the Option. The Company and GSK will form a joint steering committee, joint development committees, and joint commercialization committees responsible for coordinating all activities under the GSK Collaboration Agreement. Ownership of intellectual property developed under the GSK Collaboration Agreement is allocated between or shared by the parties depending on development and subject matter. GSK’s royalty obligations continue with respect to each country and each product until the later of (i) the date on which such product is no longer covered by certain intellectual property rights in such country and (ii) the 10th anniversary of the first commercial sale of such product in such country. Each party has the right to sublicense its rights under the GSK Collaboration Agreement subject to certain conditions. The GSK Collaboration Agreement will continue in effect on a product-by-product and country-by-country basis until the expiration of the obligation to make payments under the GSK Collaboration Agreement with respect to such product in each country, unless earlier terminated by either party pursuant to its terms. Either the Company or GSK may terminate the GSK Collaboration Agreement for the other party’s insolvency or certain uncured breaches. The Company may terminate the GSK Collaboration Agreement if GSK or any of its sublicensees or affiliates challenge certain patents of the Company. GSK may terminate the GSK Collaboration Agreement in its entirety or on a target-by-target basis upon 90-day notice to the Company. Pfizer Clinical Trial Collaboration and Supply Agreements In March 2020, the Company entered into a clinical trial collaboration and supply agreement with Pfizer Inc., or the Supply Agreement, as amended in September 2020, April 2021 and August 2021. Pursuant to the Supply Agreement, Pfizer supplies the Company with their MEK inhibitor, binimetinib, and their cMET inhibitor, crizotinib, to evaluate combinations of darovasertib independently with each of the Pfizer compounds, in patients with tumors harboring activating GNAQ or GNA11 hotspot mutations. Under the Supply Agreement, the Company will sponsor a Phase 1/2 clinical trial, and Pfizer will supply the Company with binimetinib and crizotinib for use in the clinical trial at no cost to the Company. The Supply Agreement provides that the Company and Pfizer will jointly own clinical data generated from the clinical trial. In March 2022, we and Pfizer entered into the Second Pfizer Agreement pursuant to which we may, subject to FDA feedback and guidance, evaluate darovasertib and crizotinib, as a combination therapy in MUM in a planned Phase 2/3 potential registration-enabling clinical trial. Pursuant to the Second Pfizer Agreement, we are the sponsor of the planned combination trial and we will provide darovasertib and pay for the costs of the combination trial; Pfizer will provide crizotinib for the planned combination trial at no cost to us for up to an agreed-upon number of MUM patients. Separately, in March 2022, we and Pfizer also entered into the Third Pfizer Agreement pursuant to which we may, subject to preclinical validation and FDA feedback and guidance, evaluate darovasertib and Pfizer’s cMET inhibitor, crizotinib, as a combination therapy in cMET-driven tumors such as NSCLC and/or HCC in a Phase 1 clinical trial. Pursuant to the Third Pfizer Agreement, we are the sponsor of the planned combination trial, and we will provide darovasertib and pay for the costs of the combination trial; Pfizer will provide crizotinib for the planned combination trial at no cost to us. On May 12, 2023, we continued our relationship with Pfizer by entering into Amendment No. 4 to the Pfizer Agreement relating to the supply of crizotinib in support of this Phase 2 clinical trial, pursuant to which Pfizer will continue to provide IDEAYA with an additional defined quantity of crizotinib at no cost. We also expanded our relationship with Pfizer in May 2023 under an Amendment No. 1 to the Second Pfizer Agreement to support the Phase 2/3 registrational trial to evaluate darovasertib and crizotinib as a combination therapy in MUM. Under the as-amended Second Pfizer Agreement, Pfizer will provide us with a first defined quantity of crizotinib at no cost, as well as an additional second defined quantity of crizotinib at a lump-sum cost. Novartis License Agreement In September 2018, the Company entered into a license agreement with Novartis International Pharmaceuticals Ltd. (“Novartis”) to develop and commercialize Novartis’ LXS196 (also known as IDE196), a Phase 1 protein kinase C (“PKC”) inhibitor for the treatment of cancers having GNAQ and GNA11 mutations. Under the license agreement, the Company is liable to make contingent development and sales-based milestone payments of up to $ 29.0 million and mid to high single-digit royalty payments based on net sales of the licensed products. Because the achievement of these milestones had not occurred or was not considered probable as of June 30, 2023, such contingencies have not been recorded in the Company's condensed consolidated financial statements. Amgen Clinical Trial Collaboration and Supply Agreement In July 2022, the Company entered into a clinical collaboration and supply agreement with Amgen , Inc. (“Amgen”) to clinically evaluate IDE397, the Company's investigational MAT2A inhibitor, in combination with AMG 193, the Amgen investigational small molecule MTA-cooperative inhibitor of PRMT5, in patients having MTAP-null solid tumors, in a Phase 1/2 clinical trial (the “Amgen CTCSA"). Under the mutually non-exclusive Amgen CTCSA, the Company will provide IDE397 drug supply to Amgen, who will be the sponsor of the Phase 1 clinical combination trial evaluating IDE397 and AMG 193. The Company and Amgen will jointly share external costs of the study and will jointly oversee clinical development of the combination therapy through a Joint Oversight Committee responsible for coordinating all regulatory and other activities under the Amgen CTCSA. The parties will jointly own collaboration data and combination-related intellectual property, if any, arising from the combination clinical trial. The Company and Amgen each retain commercial rights to their respective compounds, including with respect to use as a monotherapy agent or combination agent. Cancer Research Technology Ltd. and University of Manchester Exclusive Option and License Agreement In January 2022, the Company exercised its option for an exclusive worldwide license covering a broad class of PARG inhibitors from Cancer Research Technology Ltd. (CRT) and the University of Manchester, and in connection therewith, paid a one-time option exercise fee of £ 250,000 . The Company will be obligated to make payments to CRT aggregating up to £ 19.5 million upon the achievement of specific development and regulatory approval events for development of a PARG inhibitor in oncologic diseases. The Company will also pay low single-digit tiered royalties, and potentially also sales-based milestones, to CRT based on net sales of licensed products. In addition, in the event the Company sublicenses the intellectual property, it will also be obligated to pay CRT a specified percentage of any sublicense revenue. In April 2023, we incurred an obligation to pay milestone payments in an aggregate amount of £ 750,000 to CRT based upon the achievement of certain milestones relating to first and second tumor histologies in connection with the Phase 1 portion of the Phase 1/2 clinical trial in oncologic diseases.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue Recognition	10. Revenue Recognition The Company recognizes revenue in accordance with ASC 606 for the GSK Collaboration Agreement (see Note 9, Significant Agreements). Disaggregation of Revenue The following table presents revenue disaggregated by research program (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 MAT2A $ 41 $ 3,740 $ 211 $ 11,599 Pol Theta 33 1,224 171 3,344 WRN 3,470 887 11,042 2,267 Total collaboration revenue $ 3,544 $ 5,851 $ 11,424 $ 17,210 Contract balances The following table presents the significant changes in the balance of contract liabilities during the six months ended June 30, 2023 (in thousands): Contract liabilities Balance as of December 31, 2022 $ 13,753 Reclassification to revenue, as the result of performance obligations satisfied ( 11,424 ) Increase in accounts receivable 489 Balance as of June 30, 2023 $ 2,818 The timing of revenue recognition, billings, and cash collections results in accounts receivable, contract assets, and contract liabilities on the balance sheets. Based on the estimated reimbursable program costs for a quarter, the Company recognizes accounts receivable, which are derecognized upon reimbursement. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded. Contract liabilities are derecognized as revenue after control of the products or services is transferred to the customer and all revenue recognition criteria have been met. Performance obligations The Company has identified the following six performance obligations associated with the GSK Collaboration Agreement: (i) Preclinical and Phase 1 Monotherapy clinical research and development services under the MAT2A program (“MAT2A R&D Services”) (ii) Preclinical research services and the related license to IDEAYA-owned technology under the Pol Theta program (“Pol Theta R&D Services”) (iii) Preclinical research services and the related license to IDEAYA-owned technology under the WRN program (“WRN R&D Services”) (iv) Material right associated with the option to license IDEAYA-owned technology under the MAT2A program (“Option”) (v) Material right associated with the option to license to IDEAYA-owned technology under the MAT2A program to the extent necessary for preclinical activities in preparation for the MAT2A Combination Trial (“Preclinical MAT2A License”) (vi) Material right associated with the supply of MAT2A product for the MAT2A Combination Trial (“MAT2A Supply”) The Company recognizes revenue related to amounts allocated to the MAT2A R&D services as the underlying services are performed over the period through the delivery of the Option data package, which is generated from its conduct of the dose escalation portion of the MAT2A Phase 1 monotherapy clinical trial. The Company uses its internal research and development capability and also engages third-party clinical research organizations, or CROs, for which the Company acts as a principal. The Company has delivered the Option data package to GSK. Accordingly, the performance obligation related to the MAT2A R&D services has been fulfilled. With respect to the Pol Theta and WRN programs, the Company identified two promises: (1) granting of the license to develop and commercialize Pol Theta and WRN products, respectively, and (2) the preclinical research services. The Company has determined that these two promises are not distinct within the context of the contract. As of the Effective Date of the GSK Collaboration Agreement, both programs were at an early stage, and the Company was yet to identify any development candidate for either program, which will require the completion of certain preclinical studies. After the Company and GSK identify a development candidate, a series of IND-enabling studies will be conducted before an Investigational New Drug application is submitted to the FDA. Due to the early stage of development, the Company’s preclinical research services are expected to transform the underlying technology and significantly modify or customize the license. Therefore, the two promises are not distinct from each other and are accounted for as a single performance obligation for each of the Pol Theta and WRN programs, respectively. In June 2022, the Company announced the nomination of Pol Theta Helicase Inhibitor DC and in August 2022, announced the achievement of an initial preclinical development milestone in connection with ongoing IND-enabling studies to support evaluation of Pol Theta Helicase Inhibitor DC. The Company recognized revenue related to amounts allocated to the Pol Theta R&D Services and WRN R&D Services as the underlying services are performed over the period through the completion of the Pol Theta and WRN preclinical research programs, respectively. Within 90 days from the end of each calendar quarter, GSK reimbursed the Pol Theta program costs incurred by the Company. Within 75 days from the end of each calendar quarter, the Company and GSK determined the amounts of WRN program costs incurred by both parties and the net amount owed by GSK to the Company or by the Company to GSK, which was paid within 75 days from such determination by a reimbursing party. The Company used its internal research capability and may also engage third-party clinical research organizations, or CROs, in transferring the Pol Theta R&D services and WRN R&D services, for which the Company acts as a principal. The Company completed Pol Theta R&D services during December 2022. Accordingly, the performance obligation related to the Pol Theta R&D services has been fulfilled. The remaining contract liabilities under the GSK Collaboration Agreement relate entirely to the Company’s remaining performance obligations for WRN R&D Services and are classified as short-term contract liabilities, based on our current expectation to complete the performance obligations relating to WRN R&D Services within the next 12-months period. Accordingly, the Company anticipates that future revenue amounts to be recognized related to previously received upfront payments and amounts due and payable to us for research and development services will be variable and will decrease over this next 12-month period. In the future, recognition of revenue may be based on additional milestone payments, profit sharing, and royalties on any net product sales under the GSK Collaboration Agreement. We expect that any revenue we generate will fluctuate from period to period as a result of various factors, such as period to period variability in milestone achievements for the Pol Theta or WRN programs. Subject to exercise of the Option, at Option closing following HSR clearance, GSK would have obtained an exclusive license to develop and commercialize MAT2A products. The Company has concluded that this Option results in a material right as the option exercise fee contains a discount that GSK would not have otherwise received. The Company has determined the nature of the license to develop and commercialize MAT2A products to be functional. The Company delivered an Option data package to GSK pursuant to the GSK Collaboration Agreement comprising preclinical and clinical data resulting from the Company's conduct of a dose-escalation portion of the MAT2A Phase 1 monotherapy clinical trial, following which, the Option was exercisable by GSK within a specified period of time. In August 2022, the Company received notice from GSK waiving its rights to exercise its Option to obtain an exclusive license to further develop and commercialize IDE397, as well as other IDEAYA compounds, if any, directly targeting MAT2A, or the GSK MAT2A Option Waiver, pursuant to the GSK Collaboration Agreement. As such, the Company retains and fully owns all right, title and interest in and to IDE397 and the MAT2A program, including all worldwide commercial rights thereto. The Company will be responsible for the costs of further research and clinical development activities that the Company conducts for the MAT2A program following the GSK MAT2A Option Waiver. Accordingly, the Company recognized revenue of $ 17.4 million related to GSK's waiver of its rights to exercise its Option during the year ended December 31, 2022. If GSK had elected to conduct the MAT2A Combination Trial, the Company would have an obligation to supply MAT2A product to be used for the MAT2A Combination Trial at its own cost. The Company has concluded that this supply option results in a material right as it involves a discount that GSK would not have otherwise received. The Company would have recognized revenue, as it transferred the control of the MAT2A product to GSK. In January 2022, GSK waived its rights under the GSK Collaboration Agreement to initiate, or request that the Company initiate, prior to GSK’s exercise of the Option, a Phase 1 combination clinical trial for a MAT2A product and GSK’s Type I PRMT inhibitor (GSK3368715) product, or the MAT2A Combination Trial. Accordingly, the Company has no further obligation under the GSK Collaboration Agreement to supply MAT2A product for the MAT2A Combination Trial at its own cost. The Company recognized revenue of $ 2.4 million during the year ended 2022 related to the material right to supply MAT2A compound as the material right no longer exists and the Company has no further obligation related to the MAT2A Combination Trial. Transaction price allocated to the remaining performance obligations The following table presents the transaction price allocated to the remaining performance obligations as of June 30, 2023 (in thousands): Performance Obligations Allocation of Transaction Price WRN R&D Services 2,818 Total transaction price allocated to the remaining performance obligations $ 2,818 The Company applies the sales-based royalty exception to the commercial milestones and tiered royalties for all programs because GSK would ascribe significantly more value to the license than to the other goods or services to which the commercial milestones and tiered royalties relate. The Company will be entitled to receive the commercial milestones either when the first commercial sale occurs, or when the predefined net sales in a calendar year are achieved, upon which the variability will be resolved. Also, the Company will be entitled to receive the tiered royalties during a calendar year when global net sales of each product occur, upon which the variability will be resolved.

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Common Stockholders	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Common Stockholders	11. Net Loss Per Share Attributable to Common Stockholders The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data): Three Months Ended Six Months Ended 2023 2022 2023 2022 Numerator: Net loss attributable to common stockholders $ ( 27,926 ) $ ( 22,056 ) $ ( 51,566 ) $ ( 36,069 ) Denominator: Weighted-average shares outstanding 56,251,130 38,660,971 52,332,373 38,626,659 Weighted-average shares used in computing net loss (1) 56,251,130 38,660,971 52,332,373 38,626,659 Net loss per share attributable to common stockholders, $ ( 0.50 ) $ ( 0.57 ) $ ( 0.99 ) $ ( 0.93 ) (1) The shares underlying the pre-funded warrants to purchase shares of the Company's common stock have been included in the calculation of the weighted-average number of shares outstanding, basic and diluted, for the three and six months ended June 30, 2023. The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: As of June 30, 2023 2022 Options to purchase common stock 7,138,527 4,922,224 Total 7,138,527 4,922,224

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Events	12. Subsequent Events Subsequent to June 30, 2023, from July 1, 2023 through August 9, 2023, we sold an aggregate of 76,421 shares of our common stock for aggregate net proceeds of $ 1.7 million at a weighted average sales price of approximately $ 23.53 per share under the at-the-market offering pursuant to the June 2023 Sales Agreement with Jefferies as sales agent.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim reporting. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, the unaudited condensed financial statements should be read in conjunction with the audited financial statements and the related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC.
Unaudited Condensed Financial Statements	Unaudited Condensed Financial Statements The accompanying financial information for the three and six months ended June 30, 2023 and June 30, 2022 are unaudited. The unaudited condensed financial statements have been prepared on the same basis as the annual audited financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position as of June 30, 2023 and its results of operations for the three and six months ended June 30, 2023 and June 30, 2022 and cash flows for the six months ended June 30, 2023 and June 30, 2022 . The results for interim periods are not necessarily indicative of the results expected for the full fiscal year or any other periods.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include useful lives of property and equipment, determination of the discount rate for operating leases, accruals for research and development activities, revenue recognition, stock-based compensation, and income taxes. On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates.
Risks and Uncertainties	Risks and Uncertainties The Company operates in a dynamic and highly competitive industry and is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, contract manufacturers, contract research organizations and collaboration partners, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies and clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. The Company believes that changes in any of the following areas could have a material adverse effect on the Company’s future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials and collaboration activities; regulatory approval and market acceptance of the Company’s products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company’s ability to attract and retain employees necessary to support its growth. Products developed by the Company require approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained or maintained, that the products will receive the necessary approvals, or that any approved products will be commercially viable. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval, it could have a materially adverse impact on the Company. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees, consultants and other third parties. Beginning in late 2019, the outbreak of a novel strain of virus named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), or coronavirus, which causes coronavirus disease 2019, or COVID-19, has evolved into a global pandemic. The extent of the impact of the coronavirus outbreak on the Company’s business will depend on certain developments, including the duration and spread of the outbreak and the extent and severity of the impact on the Company’s clinical trial activities, research activities and suppliers, all of which are uncertain and cannot be predicted. At this point, the extent to which the coronavirus outbreak may materially impact the Company’s financial condition, liquidity or results of operations is uncertain. The Company has expended and will continue to expend substantial funds to complete the research, development and clinical testing of product candidates. The Company also will be required to expend additional funds to establish commercial-scale manufacturing arrangements and to provide for the marketing and distribution of products that receive regulatory approval. The Company may require additional funds to commercialize its products. The Company is unable to entirely fund these efforts with its current financial resources. If adequate funds are unavailable on a timely basis from operations or additional sources of financing, the Company may have to delay, reduce the scope of or eliminate one or more of its research or development programs which would materially and adversely affect its business, financial condition and operations.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents, marketable securities and accounts receivable. Substantially all the Company’s cash is held by two financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company’s investment policy addresses credit ratings, diversification, and maturity dates. The Company invests its cash equivalents and marketable securities in money market funds, U.S. government securities, commercial paper, and corporate bonds. The Company limits its credit risk associated with cash equivalents and marketable securities by placing them with banks and institutions it believes are creditworthy and in highly rated investments and, by policy, limits the amount of credit exposure with any one commercial issuer. The Company has not experienced any credit losses on its deposits of cash, cash equivalents or marketable securities. Accounts receivable represents amounts due from GSK. The Company monitors economic conditions to identify facts or circumstances that may indicate that any of its accounts receivable are at risk of collection.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) under its accounting standard codifications (“ASC”) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below. New Accounting Pronouncements Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes will result in earlier recognition of credit losses. For public business entities, this ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The FASB subsequently issued supplemental guidance to ASC 326 within ASU 2019-05, Financial Instruments—Credit Losses (Topic 326): Targeted Transition Relief , ASU 2019-10, Financial Instruments—Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) and ASU 2019-11, Codification Improvements to Topic 326, Financial Instruments—Credit Losses . ASU 2019-05 provides an option to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost basis. ASU 2019-10 extended the effectiveness of Topic 326 for smaller reporting companies until fiscal years beginning after December 15, 2022. ASU 2019-10 requires entities to make a one-time determination of whether an entity is eligible to be a smaller reporting company as of November 15, 2019 for the purpose of determining the effective date of ASU 2016-13. The Company determined that it was eligible to be a smaller reporting company as of November 15, 2019. The Company adopted this ASU on January 1, 2023 , and evaluated the impact of the adoption of the ASU. It did no t result in a material impact on the Company's financial statements and related disclosures.
Fair Value Measurement and Marketable Securities	The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: Level 1—Observable inputs, such as quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3—Unobservable inputs which reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model .
Share Based Compensation Forfeiture	The Company accounts for forfeitures as they occur.

Fair Value Measurement and Ma_2

Fair Value Measurement and Marketable Securities (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of Financial Assets Measured and Recognized at Fair Value	As of June 30, 2023, financial assets measured and recognized at fair value are as follows (in thousands): June 30, 2023 Amortized Gross Gross Estimated Assets U.S. government securities Level 2 $ 300,981 $ 17 $ ( 944 ) $ 300,054 Corporate bonds Level 2 42,167 — ( 214 ) 41,953 Commercial paper (1) Level 2 135,497 — ( 38 ) 135,459 Marketable securities 478,645 17 ( 1,196 ) 477,466 Money market funds (2) Level 1 32,160 — — 32,160 Total fair value of assets $ 510,805 $ 17 $ ( 1,196 ) $ 509,626 (1) $ 70.2 million was included in cash and cash equivalents on the balance sheet due to securities with purchase dates within 90 days of maturity dates (2) Included in cash and cash equivalents on the condensed balance sheets. As of December 31, 2022, financial assets measured and recognized at fair value are as follows (in thousands): December 31, 2022 Amortized Gross Gross Estimated Assets U.S. government securities Level 2 $ 146,030 $ — $ ( 2,291 ) $ 143,739 Corporate bonds Level 2 86,546 — ( 580 ) 85,966 Commercial paper (1) Level 2 78,797 — — 78,797 Marketable securities 311,373 — ( 2,871 ) 308,502 Money market funds (2) Level 1 64,153 — — 64,153 Total fair value of assets $ 375,526 $ — $ ( 2,871 ) $ 372,655 (1) $ 4.0 million was included in cash and cash equivalents on the balance sheet due to securities with purchase dates within 90 days of maturity dates (2) Included in cash and cash equivalents on the condensed balance sheets.

Balance Sheet Components (Table

Balance Sheet Components (Tables)	6 Months Ended
	Jun. 30, 2023
Balance Sheet Related Disclosures [Abstract]
Summary of Property and Equipment, Net	Property and equipment, net consisted of the following (in thousands): Useful Life June 30, December 31, (In Years) 2023 2022 Laboratory equipment 5 $ 10,859 $ 9,743 Computer equipment 3 261 261 Software 3 231 231 Leasehold improvements Shorter of useful life or lease term 3,321 3,321 Furniture and fixtures 5 506 506 Total property and equipment 15,178 14,062 Less: Accumulated depreciation and amortization ( 8,349 ) ( 7,553 ) Property and equipment, net $ 6,829 $ 6,509
Summary of Accrued Liabilities	Accrued liabilities consisted of the following (in thousands): June 30, December 31, 2023 2022 Accrued research and development expenses $ 8,481 $ 11,146 Accrued salaries and benefits 4,500 5,248 Legal and professional fees 764 513 Other 945 92 Accrued liabilities $ 14,690 $ 16,999

Common Stock (Tables)

Common Stock (Tables)	6 Months Ended
	Jun. 30, 2023
Stockholders' Equity Note [Abstract]
Schedule of Aggregate Warrants	As of June 30, 2023, the following aggregate warrants to purchase shares of the Company’s common stock were issued and outstanding: Issue Date Expiration Date Exercise Price per Share Number of Shares subject to Outstanding Warrants April 27, 2023 None $ 0.0001 2,020,270
Schedule of Number of Common Stock Reserved for Future Issuance	The Company had reserved common stock for future issuance as follows: June 30, December 31, 2023 2022 Outstanding options under the 2015 and 2019 Plans 7,138,527 5,097,263 Shares available for grant under the 2019 Plan 656,992 664,919 Shares available for grant under the 2023 Inducement Plan 699,800 — Shares available under the Employee Stock Purchase Plan 1,346,300 906,523 Pre-funded warrants issued and outstanding 2,020,270 — Total 11,861,889 6,668,705

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Summary of Stock-Based Compensation Expense	Total stock-based compensation expense recorded related to awards granted to employees and non-employees was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Research and development $ 2,705 $ 1,603 $ 4,792 $ 2,901 General and administrative 2,026 1,441 3,598 2,748 Total stock-based compensation expense $ 4,731 $ 3,044 $ 8,390 $ 5,649
Summary of Activity under Plans	Activity under the Company’s 2015 and 2019 Plans and 2023 Inducement Plan is set forth below: Outstanding Options Shares Weighted- Weighted- Aggregate Intrinsic Value (Millions) Balance, January 1, 2023 5,097,263 $ 12.93 7.84 $ 29.58 Options granted 2,433,571 $ 18.06 Options exercised ( 194,590 ) $ 9.52 Options canceled ( 197,717 ) $ 17.80 Balance, June 30, 2023 7,138,527 $ 14.64 8.15 $ 63.08 Exercisable as of June 30, 2023 2,849,704 $ 11.32 6.64 $ 34.54 Vested and expected to vest as of 7,138,527 $ 14.64 8.15 $ 63.08
Assumptions Used to Calculate Fair Values of Options	The fair values of options were calculated using the assumptions set forth below: Three Months Ended June 30, Six months Ended June 30, 2023 2022 2023 2022 Expected term 6.1 years 6.1 years 6.1 years 6.1 years Expected volatility 85.2 % - 86.4 % 87.5 % - 87.8 % 85.2 % - 86.9 % 87.5 % - 89.9 % Risk-free interest rate 3.6 % - 4.1 % 2.7 % - 3.0 % 3.6 % - 4.1 % 1.6 % - 3.0 % Dividend yield 0 % 0 % 0 % 0 %

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Summary of Revenue Disaggregated by Research Program	The following table presents revenue disaggregated by research program (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 MAT2A $ 41 $ 3,740 $ 211 $ 11,599 Pol Theta 33 1,224 171 3,344 WRN 3,470 887 11,042 2,267 Total collaboration revenue $ 3,544 $ 5,851 $ 11,424 $ 17,210
Summary of Contract Balances	The following table presents the significant changes in the balance of contract liabilities during the six months ended June 30, 2023 (in thousands): Contract liabilities Balance as of December 31, 2022 $ 13,753 Reclassification to revenue, as the result of performance obligations satisfied ( 11,424 ) Increase in accounts receivable 489 Balance as of June 30, 2023 $ 2,818
Summary of Transaction Price Allocated to Remaining Performance Obligations	The following table presents the transaction price allocated to the remaining performance obligations as of June 30, 2023 (in thousands): Performance Obligations Allocation of Transaction Price WRN R&D Services 2,818 Total transaction price allocated to the remaining performance obligations $ 2,818

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Common Stockholders (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders	The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data): Three Months Ended Six Months Ended 2023 2022 2023 2022 Numerator: Net loss attributable to common stockholders $ ( 27,926 ) $ ( 22,056 ) $ ( 51,566 ) $ ( 36,069 ) Denominator: Weighted-average shares outstanding 56,251,130 38,660,971 52,332,373 38,626,659 Weighted-average shares used in computing net loss (1) 56,251,130 38,660,971 52,332,373 38,626,659 Net loss per share attributable to common stockholders, $ ( 0.50 ) $ ( 0.57 ) $ ( 0.99 ) $ ( 0.93 ) (1) The shares underlying the pre-funded warrants to purchase shares of the Company's common stock have been included in the calculation of the weighted-average number of shares outstanding, basic and diluted, for the three and six months ended June 30, 2023.
Schedule of Outstanding Shares of Potentially Dilutive Securities Excluded From the Computation of Diluted Net Loss Per Share	The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: As of June 30, 2023 2022 Options to purchase common stock 7,138,527 4,922,224 Total 7,138,527 4,922,224

Organization - Additional Infor

Organization - Additional Information (Details) - USD ($)			3 Months Ended	6 Months Ended
	Jun. 26, 2023	Apr. 27, 2023	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Subsidiary Sale Of Stock [Line Items]
Warrants to purchase shares of common stock			2,020,270	2,020,270
Common stock, par value			$ 0.0001	$ 0.0001		$ 0.0001
Proceeds from issuance of common stock upon public offering, net of issuance costs				$ 153,840,000	$ 0
Accumulated deficit			$ 286,969,000	286,969,000		$ 235,403,000
Cash, cash equivalents and marketable securities			510,100,000	510,100,000
Issuance of pre-funded warrants to purchase common stock			$ 35,132,000	$ 35,132,000
Follow On Public Offering
Subsidiary Sale Of Stock [Line Items]
Common stock price per share		$ 18.4999
Proceeds from issuance of common stock upon public offering, net of issuance costs		$ 188,700,000
Gross proceeds from issuance common stock		$ 201,300,000
Follow On Public Offering | Common Stock
Subsidiary Sale Of Stock [Line Items]
Issuance of common stock, net of issuance costs, shares		8,858,121	8,858,121	8,858,121
Warrants to purchase shares of common stock		2,020,270
Proceeds from issuance of common stock upon public offering, net of issuance costs		$ 201,300,000
Common stock offering price		$ 18.5
Overallotment Option | Common Stock
Subsidiary Sale Of Stock [Line Items]
Issuance of common stock, net of issuance costs, shares		1,418,920
At The Market Offering | Common Stock
Subsidiary Sale Of Stock [Line Items]
Issuance of common stock, net of issuance costs, shares			10,124	152,284	2,173
At The Market Offering | Jefferies LLC | January 2021 Sales Agreement | Common Stock
Subsidiary Sale Of Stock [Line Items]
Common stock remained available to be sold			$ 61,800,000	$ 61,800,000
At The Market Offering | Jefferies LLC | June 2023 Sales Agreement | Common Stock
Subsidiary Sale Of Stock [Line Items]
Issuance of common stock, net of issuance costs, shares				10,124
Common stock, par value	$ 0.0001
Proceeds from issuance of common stock upon public offering, net of issuance costs				$ 200,000
Offering expenses recorded to additional paid-in capital			$ 300,000
Weighted average sales price per share			$ 23.52	$ 23.52
Common stock remained available to be sold			$ 249,800,000	$ 249,800,000
At The Market Offering | Jefferies LLC | June 2023 Sales Agreement | Common Stock | Maximum
Subsidiary Sale Of Stock [Line Items]
Sale of common stock aggregate offering price	$ 250,000,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details) - ASU 2019-12	Jun. 30, 2023
Summary Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted	true
Change in accounting principle, accounting standards update, adoption date	Jan. 01, 2023
Change in accounting principle, accounting standards update, immaterial effect	true

Fair Value Measurement and Ma_3

Fair Value Measurement and Marketable Securities - Schedule of Financial Assets Measured and Recognized at Fair Value (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities, amortized cost	$ 478,645	$ 311,373
Marketable securities, gross unrealized gains	17	0
Marketable securities, gross unrealized losses	(1,196)	(2,871)
Marketable securities, estimated fair value	477,466	308,502
Amortized Cost	510,805	375,526
Estimated Fair Value	509,626	372,655
U.S. Government Securities | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities, amortized cost	300,981	146,030
Marketable securities, gross unrealized gains	17	0
Marketable securities, gross unrealized losses	(944)	(2,291)
Marketable securities, estimated fair value	300,054	143,739
Corporate Bonds | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities, amortized cost	42,167	86,546
Marketable securities, gross unrealized gains	0	0
Marketable securities, gross unrealized losses	(214)	(580)
Marketable securities, estimated fair value	41,953	85,966
Commercial Paper | Level 2
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities, amortized cost	135,497	78,797
Marketable securities, gross unrealized gains	0	0
Marketable securities, gross unrealized losses	(38)	0
Marketable securities, estimated fair value	135,459	78,797
Money Market Funds | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Money market funds, amortized Cost	32,160	64,153
Money market funds, estimated Fair Value	$ 32,160	$ 64,153

Fair Value Measurement and Ma_4

Fair Value Measurement and Marketable Securities - Schedule of Financial Assets Measured and Recognized at Fair Value (Parenthetical) (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 102,843	$ 68,632	$ 49,106
Commercial Paper
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 70,200	$ 4,000

Fair Value Measurement and Ma_5

Fair Value Measurement and Marketable Securities - Additional Information (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Financial liabilities recognized at fair value	$ 0	$ 0
Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities remaining maturity period	2 years	2 years

Balance Sheet Components - Summ

Balance Sheet Components - Summary of Property and Equipment, Net (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Property Plant And Equipment [Line Items]
Total property and equipment	$ 15,178	$ 14,062
Less: Accumulated depreciation and amortization	(8,349)	(7,553)
Property and equipment, net	6,829	6,509
Laboratory Equipment
Property Plant And Equipment [Line Items]
Total property and equipment	$ 10,859	9,743
Property and equipment net, useful life	5 years
Computer Equipment
Property Plant And Equipment [Line Items]
Total property and equipment	$ 261	261
Property and equipment net, useful life	3 years
Software
Property Plant And Equipment [Line Items]
Total property and equipment	$ 231	231
Property and equipment net, useful life	3 years
Leasehold Improvements
Property Plant And Equipment [Line Items]
Total property and equipment	$ 3,321	3,321
Property and equipment net, useful life	Shorter of useful life or lease term
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Total property and equipment	$ 506	$ 506
Property and equipment net, useful life	5 years

Balance Sheet Components - Addi

Balance Sheet Components - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Balance Sheet Related Disclosures [Abstract]
Depreciation and amortization expense	$ 0.6	$ 0.5	$ 1.2	$ 1

Balance Sheet Components - Su_2

Balance Sheet Components - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Balance Sheet Related Disclosures [Abstract]
Accrued research and development expenses	$ 8,481	$ 11,146
Accrued salaries and benefits	4,500	5,248
Legal and professional fees	764	513
Other	945	92
Accrued liabilities	$ 14,690	$ 16,999

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Tax Examination [Line Items]
Federal or state income tax provision	$ 0	$ 0	$ 0	$ 0
Maximum
Income Tax Examination [Line Items]
Research and experimental expenditures amortize period (in years)			15 years
Minimum
Income Tax Examination [Line Items]
Research and experimental expenditures amortize period (in years)			5 years

Common Stock - Additional Infor

Common Stock - Additional Information (Details)		3 Months Ended	6 Months Ended		12 Months Ended
	Apr. 27, 2023 USD ($) $ / shares shares	Jun. 30, 2023 $ / shares shares	Jun. 30, 2023 USD ($) $ / shares shares	Jun. 30, 2022 USD ($) Vote	Dec. 31, 2022 USD ($) $ / shares shares
Class of Stock [Line Items]
Common stock, shares authorized | shares		300,000,000	300,000,000		300,000,000
Common stock, par value | $ / shares		$ 0.0001	$ 0.0001		$ 0.0001
Common stock, voting rights			Each share of common stock is entitled to one vote.
Number of common stock voting rights held per share | Vote				1
Common stock, dividends declared | $			$ 0		$ 0
Warrants to purchase shares of common stock | shares		2,020,270	2,020,270
Proceeds from issuance of common stock upon public offering, net of issuance costs | $			$ 153,840,000	$ 0
Follow On Public Offering
Class of Stock [Line Items]
Proceeds from issuance of common stock upon public offering, net of issuance costs | $	$ 188,700,000
Common Stock
Class of Stock [Line Items]
Offering price per share | $ / shares	$ 18.5
Common Stock | Follow On Public Offering
Class of Stock [Line Items]
Issuance of common stock, net of issuance costs, shares | shares	8,858,121	8,858,121	8,858,121
Offering price per share | $ / shares	$ 18.4999
Warrants to purchase shares of common stock | shares	2,020,270
Proceeds from issuance of common stock upon public offering, net of issuance costs | $	$ 201,300,000
Proceeds from issuance of common stock net of underwriting discounts and commissions and other offering expenses | $	$ 188,700,000
Common Stock | Overallotment Option
Class of Stock [Line Items]
Issuance of common stock, net of issuance costs, shares | shares	1,418,920

Common Stock - Schedule of Aggr

Common Stock - Schedule of Aggregate Warrants (Details)	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Stockholders' Equity Note [Abstract]
Issue Date	Apr. 27, 2023
Exercise Price per Share | $ / shares	$ 0.0001
Number of Shares subject to Outstanding Warrants | shares	2,020,270

Common Stock - Schedule of Numb

Common Stock - Schedule of Number of Common Stock Reserved for Future Issuance (Details) - shares	Jun. 30, 2023	Feb. 24, 2023	Dec. 31, 2022	May 31, 2019
Class Of Stock [Line Items]
Number of common stock reserved for future issuance	11,861,889		6,668,705	195,000
Pre-funded Warrants Issued and Outstanding
Class Of Stock [Line Items]
Number of common stock reserved for future issuance	2,020,270
2019 Plan
Class Of Stock [Line Items]
Number of common stock reserved for future issuance	656,992
2023 Inducement Plan
Class Of Stock [Line Items]
Number of common stock reserved for future issuance	699,800	1,000,000
Employee Stock Purchase Plan
Class Of Stock [Line Items]
Number of common stock reserved for future issuance	1,346,300		906,523
Outstanding Options | 2015 and 2019 Plans
Class Of Stock [Line Items]
Number of common stock reserved for future issuance	7,138,527		5,097,263
Shares available for grant | 2019 Plan
Class Of Stock [Line Items]
Number of common stock reserved for future issuance	656,992		664,919
Shares available for grant | 2023 Inducement Plan
Class Of Stock [Line Items]
Number of common stock reserved for future issuance	699,800

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Feb. 24, 2023	May 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares issues under ESPP			2,500,000
Common stock, initially reserved for issuance	11,861,889		11,861,889		6,668,705		195,000
Stock-based compensation expense	$ 4,731	$ 3,044	$ 8,390	$ 5,649
Weighted-average grant-date fair value of options granted			$ 13.34	$ 9.43
Aggregate intrinsic value of options exercised			$ 1,900	$ 1,000
Total unrecognized stock-based compensation expense for stock options	$ 50,500		$ 50,500		$ 28,000
Total unrecognized stock-based compensation expense, weighted-average period of recognition			2 years 10 months 17 days		2 years 7 months 24 days
Estimated dividend yield	0%	0%	0%	0%
2023 Inducement Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, initially reserved for issuance	699,800		699,800			1,000,000
2019 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Term of options			10 years
Vesting period of options			4 years
Common stock, initially reserved for issuance	656,992		656,992
2019 Equity Incentive Plan | Cliff Vesting
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period of options			1 year
2019 Equity Incentive Plan | 10% Stockholder
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Term of options			5 years
2019 Equity Incentive Plan | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares outstanding under ESPP			4%
2019 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, initially reserved for issuance	1,346,300		1,346,300
Stock-based compensation expense			$ 300	$ 200
Maximum offering period under ESPP				27 months
Maximum eligible rate of compensation	15%		15%
2019 Employee Stock Purchase Plan | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of the fair value of common stock	85%		85%
Shares outstanding under ESPP			1%
Maximum number of shares purchasable	4,000		4,000

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 4,731	$ 3,044	$ 8,390	$ 5,649
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	2,705	1,603	4,792	2,901
General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 2,026	$ 1,441	$ 3,598	$ 2,748

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Activity under Plans (Details) - 2015 and 2019 Plans and 2023 Inducement Plan	6 Months Ended	12 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding Options, Shares, Beginning balance | shares	5,097,263
Outstanding Options, Shares, Options granted | shares	2,433,571
Outstanding Options, Shares, Options exercised | shares	(194,590)
Outstanding Options, Shares, Options canceled | shares	(197,717)
Outstanding Options, Shares, Ending balance | shares	7,138,527	5,097,263
Outstanding Options, Shares, Exercisable | shares	2,849,704
Outstanding Options, Shares, Vested and expected to vest | shares	7,138,527
Outstanding Options, Weighted-Average Exercise Price, Beginning balance | $ / shares	$ 12.93
Outstanding Options, Weighted-Average Exercise Price, Options granted | $ / shares	18.06
Outstanding Options, Weighted-Average Exercise Price, Options exercised | $ / shares	9.52
Outstanding Options, Weighted-Average Exercise Price, Options canceled | $ / shares	17.8
Outstanding Options, Weighted-Average Exercise Price, Ending balance | $ / shares	14.64	$ 12.93
Outstanding Options, Weighted-Average Exercise Price, Exercisable | $ / shares	11.32
Outstanding Options, Weighted-Average Exercise Price, Vested and expected to vest | $ / shares	$ 14.64
Outstanding Options, Weighted Average Remaining Contractual Term (Years)	8 years 1 month 24 days	7 years 10 months 2 days
Outstanding Options, Weighted Average Remaining Contractual Term (Years), Exercisable	6 years 7 months 20 days
Outstanding Options, Weighted Average Remaining Contractual Term (Years), Vested and expected to vest	8 years 1 month 24 days
Outstanding Options, Aggregate Intrinsic Value | $	$ 63,080	$ 29,580,000
Outstanding Options, Aggregate Intrinsic Value, Exercisable | $	34,540
Outstanding Options, Aggregate Intrinsic Value, Vested and expected to vest | $	$ 63,080

Stock-Based Compensation - Assu

Stock-Based Compensation - Assumptions Used to Calculate Fair Values of Options (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	6 years 1 month 6 days	6 years 1 month 6 days	6 years 1 month 6 days	6 years 1 month 6 days
Expected volatility, minimum	85.20%	87.50%	85.20%	87.50%
Expected volatility, maximum	86.40%	87.80%	86.90%	89.90%
Risk-free interest rate, minimum	3.60%	2.70%	3.60%	1.60%
Risk-free interest rate, maximum	4.10%	3%	4.10%	3%
Dividend yield	0%	0%	0%	0%

Significant Agreements - Additi

Significant Agreements - Additional Information (Details) $ in Millions		1 Months Ended
	Jul. 31, 2020 USD ($)	Apr. 30, 2023 GBP (£)	Jan. 31, 2023 USD ($)	Jan. 31, 2022 GBP (£)	Jun. 30, 2020 USD ($)	Sep. 30, 2018 USD ($)	Jun. 30, 2023 USD ($)
License Agreement | Cancer Research Technology and the University of Manchester
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment of one-time option exercise fee | £				£ 250,000
Payments for achievement of specific development and regulatory approval events | £				£ 19,500,000
Milestone payments relating to first and second tumor histologies | £		£ 750,000
Maximum | License Agreement | Novartis International Pharmaceuticals Limited
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent development and sales-based milestone payments						$ 29
GSK Collaboration Agreement | GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development and regulatory milestone payment eligible to receive							$ 3
GSK Collaboration Agreement | GSK | License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment	$ 100
Number of days of notice period for terminating agreement					90 days
Pol Theta Program
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment received for achievement of initial preclinical development milestone			$ 3
Pol Theta Program | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development and regulatory milestone payment eligible to receive					$ 485
Commercial milestone payment eligible to receive					$ 475
Preclinical development milestone payment potential to receive			$ 7
WRN Program
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development costs sharing percentage					20%
Percentage of profit share					50%
WRN Program | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Commercial milestone payment eligible to receive					$ 475
Development milestone payment eligible to receive					$ 485
WRN Program | GSK
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development costs sharing percentage					80%

Revenue Recognition - Summary o

Revenue Recognition - Summary of Revenue Disaggregated by Research Program (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disaggregation Of Revenue [Line Items]
Total collaboration revenue	$ 3,544	$ 5,851	$ 11,424	$ 17,210
MAT2A Program
Disaggregation Of Revenue [Line Items]
Total collaboration revenue	41	3,740	211	11,599
Pol Theta Program
Disaggregation Of Revenue [Line Items]
Total collaboration revenue	33	1,224	171	3,344
WRN Program
Disaggregation Of Revenue [Line Items]
Total collaboration revenue	$ 3,470	$ 887	$ 11,042	$ 2,267

Revenue Recognition - Summary_2

Revenue Recognition - Summary of Changes in Contract Liabilities (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Abstract]
Balance as of December 31, 2022	$ 13,753
Reclassification to revenue, as the result of performance obligations satisfied	(11,424)
Increase in accounts receivable	489
Balance as of June 30, 2023	$ 2,818

Revenue Recognition - Performan

Revenue Recognition - Performance Obligations - Additional Information (Details) $ in Millions		6 Months Ended	12 Months Ended
	Jul. 27, 2020 Obligation	Jun. 30, 2023	Dec. 31, 2022 USD ($)
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Reimbursement period of costs incurred for quarter ended		75 days
MAT2A Supply
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue recognized			$ 2.4
GSK
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Reimbursement period of costs incurred for quarter ended		75 days
Revenue recognized			$ 17.4
GSK Collaboration Agreement
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Number of performance obligations | Obligation	6
Pol Theta Program
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Reimbursement period of costs incurred for quarter ended		90 days
WRN Program
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Reimbursement period of costs incurred for quarter ended		75 days
Determination period of costs incurred		75 days

Revenue Recognition - Perform_2

Revenue Recognition - Performance Obligations (Additional Information) (Details 1)	Jun. 30, 2023
GSK Collaboration Agreement | WRN R&D Services | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected period to complete remaining performance obligations	12 months

Revenue Recognition - Summary_3

Revenue Recognition - Summary of Transaction Price Allocated to Remaining Performance Obligations (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation, Amount	$ 2,818
WRN R&D Services
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation, Amount	$ 2,818

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Numerator:
Net loss attributable to common stockholders	$ (27,926)	$ (22,056)	$ (51,566)	$ (36,069)
Denominator:
Weighted-average shares outstanding	56,251,130	38,660,971	52,332,373	38,626,659
Weighted average number of common shares outstanding used in computing net loss per share, basic	56,251,130	38,660,971	52,332,373	38,626,659
Weighted average number of common shares outstanding used in computing net loss per share, diluted	56,251,130	38,660,971	52,332,373	38,626,659
Net loss per share attributable to common stockholders, basic	$ (0.50)	$ (0.57)	$ (0.99)	$ (0.93)
Net loss per share attributable to common stockholders, diluted	$ (0.50)	$ (0.57)	$ (0.99)	$ (0.93)

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders - Schedule of Outstanding Shares of Potentially Dilutive Securities Excluded From the Computation of Diluted Net Loss Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities	7,138,527	4,922,224
Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities	7,138,527	4,922,224

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended	6 Months Ended
	Jul. 17, 2023	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2022
Subsequent Event [Line Items]
Proceeds from issuance of common stock upon public offering, net of issuance costs			$ 153,840	$ 0
At The Market Offering | Common Stock
Subsequent Event [Line Items]
Issuance of common stock, net of issuance costs, shares		10,124	152,284	2,173
At The Market Offering | Jefferies LLC | June 2023 Sales Agreement | Common Stock
Subsequent Event [Line Items]
Issuance of common stock, net of issuance costs, shares			10,124
Proceeds from issuance of common stock upon public offering, net of issuance costs			$ 200
Weighted average sales price per share		$ 23.52	$ 23.52
Subsequent Event | At The Market Offering | Jefferies LLC | June 2023 Sales Agreement | Common Stock
Subsequent Event [Line Items]
Issuance of common stock, net of issuance costs, shares	76,421
Proceeds from issuance of common stock upon public offering, net of issuance costs	$ 1,700
Weighted average sales price per share	$ 23.53